https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index en-au 5 Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:48943 Wed 19 Apr 2023 13:52:09 AEST ]]> The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> Delay from treatment start to full effect of immunotherapies for multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:39111 Tue 21 Mar 2023 17:45:24 AEDT ]]>